Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mark Shlapobersky

A Vaxfectin®-Adjuvanted HSV-2 Plasmid DNA Vaccine Is Effective for Prophylactic and Therapeutic Use in the Guinea Pig Model of Genital Herpes

Vaccine

English

Related publications

Duration of Protection From Live Attenuated vs. Sub Unit HSV-2 Vaccines in the Guinea Pig Model of Genital Herpes: Reassessing Efficacy Using Endpoints From Clinical Trials

PLoS ONE

Multidisciplinary

2019

English

A VP26-mNeonGreen Capsid Fusion HSV-2 Mutant Reactivates From Viral Latency in the Guinea Pig Genital Model With Normal Kinetics

English

A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection Against HSV-1 and HSV-2 Genital Infections

English

Effects of Anal Compared to Vaginal Inoculation Site on Primary/Recurrent Genital HSV-2 Disease in Guinea Pig Model. † 1023

English

The Burden of Infection With HSV-1 and HSV-2 in England and Wales: Implications for the Changing Epidemiology of Genital Herpes

Sexually Transmitted Infections

Dermatology

Infectious Diseases

2000

English

Proportion of Herpes Simplex Virus (HSV) Type 1 and Type 2 Among Genital and Extragenital HSV Isolates

Acta Dermato-Venereologica

Dermatology

Medicine

2002

English

HSV-2: In Pursuit of a Vaccine

Journal of Clinical Investigation

Medicine

2011

English

Painful Failure of Promising Genital Herpes Vaccine

Science

Multidisciplinary

Philosophy of Science

History

2010

English

Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs With the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4+ and CD8+ TRM Cells Associated With Protection Against Recurrent Genital Herpes

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mark Shlapobersky

A Vaxfectin®-Adjuvanted HSV-2 Plasmid DNA Vaccine Is Effective for Prophylactic and Therapeutic Use in the Guinea Pig Model of Genital Herpes

Related publications

Duration of Protection From Live Attenuated vs. Sub Unit HSV-2 Vaccines in the Guinea Pig Model of Genital Herpes: Reassessing Efficacy Using Endpoints From Clinical Trials

A VP26-mNeonGreen Capsid Fusion HSV-2 Mutant Reactivates From Viral Latency in the Guinea Pig Genital Model With Normal Kinetics

A Lentiviral Vector-Based, Herpes Simplex Virus 1 (HSV-1) Glycoprotein B Vaccine Affords Cross-Protection Against HSV-1 and HSV-2 Genital Infections

Effects of Anal Compared to Vaginal Inoculation Site on Primary/Recurrent Genital HSV-2 Disease in Guinea Pig Model. † 1023

The Burden of Infection With HSV-1 and HSV-2 in England and Wales: Implications for the Changing Epidemiology of Genital Herpes

Proportion of Herpes Simplex Virus (HSV) Type 1 and Type 2 Among Genital and Extragenital HSV Isolates

HSV-2: In Pursuit of a Vaccine

Painful Failure of Promising Genital Herpes Vaccine

Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs With the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4+ and CD8+ TRM Cells Associated With Protection Against Recurrent Genital Herpes